石药集团抗肿瘤新药拟纳入突破性治疗品种，默沙东癌症1类新药在中国获批临床

医药经济报2025-02-21

西罗莫司（sirolimus）又称为雷帕霉素，是一种常用的特异性mTOR抑制剂。根据石药集团公开资料，该公司的注射用西罗莫司（白蛋白结合型）是采用特殊技术将西罗莫司包裹于人血白蛋白中，实现了西罗莫司的注射给药，且无需激素预处理，同时拓展了该药物的应用领域。西罗莫司是一种大环内酯抗生素类免疫抑制剂，为mTOR特异性抑制剂。mTOR是一类丝/苏氨酸激酶，细胞内存在mTORC1和mTORC2两种复合体，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2513693782?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-21 19:18","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2513693782","market":"hk","top_or_hot":-1,"title":"石药集团抗肿瘤新药拟纳入突破性治疗品种，默沙东癌症1类新药在中国获批临床","media":"医药经济报","content":"<div>\n<p>西罗莫司（sirolimus）又称为雷帕霉素，是一种常用的特异性mTOR抑制剂。根据石药集团公开资料，该公司的注射用西罗莫司（白蛋白结合型）是采用特殊技术将西罗莫司包裹于人血白蛋白中，实现了西罗莫司的注射给药，且无需激素预处理，同时拓展了该药物的应用领域。西罗莫司是一种大环内酯抗生素类免疫抑制剂，为mTOR特异性抑制剂。mTOR是一类丝/苏氨酸激酶，细胞内存在mTORC1和mTORC2两种复合体，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221193538abd78288&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团抗肿瘤新药拟纳入突破性治疗品种，默沙东癌症1类新药在中国获批临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团抗肿瘤新药拟纳入突破性治疗品种，默沙东癌症1类新药在中国获批临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-21 19:18 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221193538abd78288&s=b><strong>医药经济报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>西罗莫司（sirolimus）又称为雷帕霉素，是一种常用的特异性mTOR抑制剂。根据石药集团公开资料，该公司的注射用西罗莫司（白蛋白结合型）是采用特殊技术将西罗莫司包裹于人血白蛋白中，实现了西罗莫司的注射给药，且无需激素预处理，同时拓展了该药物的应用领域。西罗莫司是一种大环内酯抗生素类免疫抑制剂，为mTOR特异性抑制剂。mTOR是一类丝/苏氨酸激酶，细胞内存在mTORC1和mTORC2两种复合体，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221193538abd78288&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0067412154.USD","symbol_name":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221193538abd78288&s=b","article_id":"2513693782","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221193538abd78288&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2513693782","pubTimestamp":1740136713,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"此前临床已有口服制剂的西罗莫司获批，用于预防接受肾移植患者的器官排斥。默沙东癌症1类新药在中国获批临床日前，中国国家药监局药品审评中心最新公示，默沙东申报的1类新药注射用MK-6070获得临床试验默示许可，拟开发治疗小细胞肺癌。根据公开渠道查询，本次是该产品首次在中国获批IND。两家公司将在全球范围内共同分担研发和商业化费用，而默沙东将收到1.7亿美元的预付款。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","MRK":"默沙东","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","BK1191":"制药","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1515":"抗疫概念","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","01093":"石药集团","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK1521":"挪威政府全球养老基金持仓","LU0140636845.USD":"施罗德大中华区股票A Acc"},"translate_title":"CSPC's new anti-tumor drug plans to be included in breakthrough therapeutic varieties, and Merck's new cancer class 1 drug has been approved for clinical use in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1,"MRK":0.9},"content_text":"西罗莫司（sirolimus）又称为雷帕霉素，是一种常用的特异性mTOR抑制剂。根据石药集团公开资料，该公司的注射用西罗莫司（白蛋白结合型）是采用特殊技术将西罗莫司包裹于人血白蛋白中，实现了西罗莫司的注射给药，且无需激素预处理，同时拓展了该药物的应用领域。西罗莫司是一种大环内酯抗生素类免疫抑制剂，为mTOR特异性抑制剂。mTOR是一类丝/苏氨酸激酶，细胞内存在mTORC1和mTORC2两种复合体，其信号通路的稳定性会影响T细胞中细胞因子的表达，并参与免疫抑制，影响DNA转录，调节细胞的生长与凋亡。此前临床已有口服制剂的西罗莫司获批，用于预防接受肾移植患者的器官排斥。石药集团研发的注射用西罗莫司（白蛋白结合型）可以克服口服制剂无法向靶部位递送足够浓度药量的缺点，有望实现治疗mTOR信号通路驱动的一系列疾病。根据CDE官网查询，该产品已经针对多项癌症适应症获得临床试验默示许可，包括联合多靶点抑制剂SYHA1813口服溶液治疗二线及以上晚期肾细胞癌；联合盐酸伊立替康脂质体注射液治疗小细胞肺癌；联合内分泌治疗经标准治疗失败的HR阳性、HER2阴性晚期乳腺癌等。临床前研究结果显示该产品在多种实体瘤和血液瘤模型中有较好的抗肿瘤活性。默沙东癌症1类新药在中国获批临床日前，中国国家药监局药品审评中心（CDE）最新公示，默沙东（MSD）申报的1类新药注射用MK-6070获得临床试验默示许可，拟开发治疗小细胞肺癌。公开资料显示，MK-6070（曾用名：HPN328）是一种靶向DLL3的三特异性T细胞接合器。根据公开渠道查询，本次是该产品首次在中国获批IND。公开资料显示，MK-6070是靶向DLL3的T细胞接合器，其包含3个结合域，用于引导T细胞杀死表达DLL3的癌细胞，包括抗DLL3用于靶向结合，抗CD3用于T细胞结合，抗白蛋白用于延长半衰期。DLL3是一种Notch抑制性配体，在小细胞肺癌（SCLC）和其他神经内分泌肿瘤中高度表达，在正常组织中则极少表达，因此是一个有前景的治疗靶点。2024年1月，默沙东宣布以约6.8亿美元收购Harpoon Therapeutics公司，从而获得一系列T细胞接合器在研疗法，包括彼时处于1/2期临床开发阶段的MK-6070。Harpoon Therapeutics在肿瘤免疫治疗领域取得了重大进展，基于三特异性T细胞激活构件（TriTAC）平台开发了一系列创新T细胞结合器，这种工程化蛋白技术旨在引导患者自身的免疫细胞攻击肿瘤细胞。2024年8月，第一三共（Daiichi Sankyo）和默沙东宣布扩展现有的全球共同开发和商业化协议，在三种在研DXd抗体偶联药物之外添加默沙东的在研疗法MK-6070。两家公司将在全球范围内共同分担研发和商业化费用，而默沙东将收到1.7亿美元的预付款。编辑：晚晚审校：张松、张蓝飞同仁堂牵手百雀羚、“大树漱玉”落地！医药零售多元化再添新样本？利妥昔单抗市场内卷加剧！罗氏牵手百洋，能否把握新机遇？抢滩复方降脂药首仿！科伦、齐鲁再聚首，近20家药企重构百亿市场？CXO掀起整合潮！澎立生物“卖身”奥浦迈，“药明系”资产腾挪，市场如何破局？执业药师全面配备倒计时！叠加“挂证”专项整治，药店洗牌加速？www.yyjjb.com.cn洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2513693782","isCrawlerRequest":true}